ClinConnect ClinConnect Logo
Search / Trial NCT04294368

Targeted Fortification of Donor Breast Milk in Preterm Infants

Launched by COLUMBIA UNIVERSITY · Mar 2, 2020

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Human Milk Analyzer Miris Target Fortification Targeted Fortification Donor Breast Milk

ClinConnect Summary

This clinical trial is studying the best way to strengthen donor breast milk for premature infants. Researchers want to find out if a special method of adding nutrients, called targeted fortification, helps these babies grow better compared to the usual method, known as standard fortification. They believe that infants receiving this targeted approach will gain weight and grow more effectively.

To participate in the trial, infants must be born prematurely, specifically before 30 weeks of pregnancy and weigh 1500 grams or less at birth. Parents who choose to be part of the study will not only help researchers learn more about infant nutrition but will also have their babies receive either the standard or the targeted fortified donor breast milk. It's important to note that families cannot join if their baby has certain health issues or conditions that could affect their growth. If eligible, families can expect to closely monitor their baby’s growth during the study, providing valuable information to improve care for future premature infants.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Premature infants born \</= 30 weeks gestational age
  • Birth Weight \</= 1500 grams
  • Exclusion Criteria:
  • Parents do no consent to donor milk
  • Confounders for poor growth such as congenital heart disease, GI diagnoses such as gastroschisis and omphalocele, and or major congenital anomalies
  • Grade III or IV intraventricular hemorrhage diagnoses prior to randomization
  • Small for gestational age (\<3% on Fenton Growth Curve)
  • Failure to initiate fortified feeds prior to 3 weeks of life
  • Diagnosis of necrotizing entercolitis prior to randomization
  • Diagnosis of early onset sepsis confirmed with positive culture

About Columbia University

Columbia University, a prestigious Ivy League institution located in New York City, is a leading sponsor of clinical trials dedicated to advancing medical research and improving patient care. With a robust network of research facilities and a commitment to innovation, Columbia University collaborates with a diverse range of healthcare professionals and researchers to explore groundbreaking therapies and treatment methodologies. The university's clinical trials encompass various fields, including oncology, neurology, and public health, aiming to translate scientific discoveries into effective clinical applications. Columbia University is dedicated to maintaining the highest ethical standards and regulatory compliance, ensuring the safety and well-being of trial participants while contributing to the global body of medical knowledge.

Locations

New York, New York, United States

Patients applied

0 patients applied

Trial Officials

Marianne Garland, MD

Principal Investigator

Columbia University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials